Paragon Care : Appendix 3B – Medtek & Western Biomedical
August 13, 2017 at 11:52 pm EDT
Share
Appendix 3B
Rule 2.7, 3.10.3, 3.10.4, 3.10.5
Revision of Appendix 3B lodged 16 September 2015 New issue announcement,
application for quotation of additional securities and agreement
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.
We (the entity) give ASX the following information.
Part 1 - All issues
You must complete the relevant sections (attach sheets if there is not enough space).
1
+Class of +securities issued or to be issued
Fully paid ordinary shares
2
Number of +securities issued or to be issued (if known) or maximum number which may be issued
525,920
3
Principal terms of the
+securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if
+convertible securities, the conversion price and dates for conversion)
Fully paid ordinary shares to rank equally in all respects with existing ordinary shares.
4
Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?
If the additional +securities do not rank equally, please state:
the date from which they do
the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment
Fully paid ordinary shares ranking equally in all respects with existing ordinary shares.
5
Issue price or consideration
$0.9020 per fully paid ordinary share
6
Purpose of the issue
(If issued as consideration for the acquisition of assets, clearly identify those assets)
Part consideration for the acquisition of the Medtek business as announced on 14 August 2017 (55,432 shares)
Earn-out consideration in lieu of cash to vendor of Western Biomedical business acquired in October 2015. (470,488 shares)
6a
Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?
If Yes, complete sections 6b - 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i
Yes
6b
The date the security holder resolution under rule 7.1A was passed
18 November 2016
6c
Number of +securities issued without security holder approval under rule 7.1
525,920, being the above issues.
6d
Number of +securities issued with security holder approval under rule 7.1A
Nil
6e
Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)
Nil
6f
Number of +securities issued under an exception in rule 7.2
764,447
6g
If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the
+issue date and both values. Include the source of the VWAP calculation.
N/A
6h
If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements
N/A
6i
Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A - complete Annexure 1 and release to ASX Market Announcements
40,728,582
Refer Annexure 1
7
+Issue dates
Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.
Cross reference: item 33 of Appendix 3B.
14 August 2017
Number
+Class
165,543,929
Fully paid ordinary shares
Number and +class of all
+securities quoted on ASX (including the +securities in section 2 if applicable)
Number
+Class
N/A
N/A
Number and +class of all
+securities not quoted on ASX (including the +securities in section 2 if applicable)
No change to dividend policy.
Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)
Part 2 - Pro rata issue
The new DRP shares are not issued pursuant to a Pro Rate Issue and questions 11 to 35 not applicable.
Part 3 - Quotation of securities
You need only complete this section if you are applying for quotation of securities
34
Type of +securities (tick one)
(a)
+Securities described in Part 1
(b)
All other +securities
Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities
Entities that have ticked box 34(a)
The new shares do not form a new class of securities and questions 35 to 37 not applicable
Paragon Care Ltd. published this content on 14 August 2017 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 14 August 2017 03:51:09 UTC.
Original documenthttp://www.paragoncare.com.au/wp-content/uploads/PGC_Appendix-3B-Medtek-Western-Bio-2017-08-14.pdf
Public permalinkhttp://www.publicnow.com/view/87C00D5F3068D569148C0FD360FFB133D9D76964
Paragon Care Limited is an Australia-based company. It is engaged in the supply of durable medical equipment, medical devices and consumable medical products and maintenance of technical medical equipment to the health, aged care and veterinary markets throughout Australia. Its segments include Diagnostic and Scientific, Devices, Capital and Consumables, and Service and Technology. Diagnostic and Scientific segment incorporates blood bank diagnostics manufacturer, clinical pathology diagnostics distribution and scientific and research and development (R&D) laboratory equipment distribution. Devices Segment incorporates ophthalmology and optometry, orthopedics, pain management, infection prevention and ortho biologics. Capital and Consumables segment includes medical, surgical and veterinary services. Service and Technology segment includes offering from biomedical devices to high end capital equipment, service support and technology management and service partnership with brands.